Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 20, 2018

SELL
$4.0 - $6.54 $30,976 - $50,645
-7,744 Reduced 28.27%
19,648 $81,000
Q3 2017

Nov 08, 2017

BUY
$4.99 - $6.57 $136,686 - $179,965
27,392
27,392 $168,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Dixon Hubard Feinour & Brown Inc Portfolio

Follow Dixon Hubard Feinour & Brown Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dixon Hubard Feinour & Brown Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dixon Hubard Feinour & Brown Inc with notifications on news.